In BALB/c mice with severe combined immune deficiency, primary T cells expressing chimeric receptors that were reactive for HER2 proteins were tested for their adjuvant therapeutic efficacy against mouse mammary carcinoma 4T1.2 cells expressing human erbB-2 in comparison with the effects of the commonly used adjuvants, 5-FU, as well as doxorubicin and Herceptin [18]. Here, ERBB2 is linked to Immunodeficiency.